Stocks Health care GSK
NYSE · Health careGSK plc (GSK)
GSK plc reported revenue of £32.7B in fiscal 2025, up 4.1% from a year earlier. Net income was £5.7B, a net margin of 17.5%. Operating cash flow minus capital spending left £6.4B of free cash flow in fiscal 2025. At December 31, 2025 it held £3.4B in cash against £14.5B of debt.
Key facts about GSK plc
- Net worth
- GSK plc has a market value (market cap) of $96.7B at the latest share price, and shareholders' equity of £16.4B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was £32.7B (+4.1% year on year), with net income of £5.7B.
- Cash flow
- In fiscal 2025 operations brought in £7.7B of cash; after £1.3B of capital spending, free cash flow was £6.4B.
What GSK plc does
GSK is a biopharmaceutical company that researches, develops, and manufactures prescription medicines and vaccines. Its product portfolio focuses on infectious diseases, human immunodeficiency virus (HIV) treatments, immunology, and oncology. Its medicines and vaccines are sold to healthcare systems, hospitals, pharmacies, and governments globally. Its shares trade on NYSE under the ticker GSK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | £32.7B | £5.7B | £1.39 | £6.4B |
| 2024 | £31.4B | £2.6B | £0.62 | £5.2B |
| 2023 | £30.3B | £4.9B | £1.20 | £5.5B |
| 2022 | £29.3B | £15B | £3.66 | £6.3B |
| 2021 | £24.7B | £4.4B | £1.08 | £7B |
| 2020 | £24.4B | £5.7B | £1.43 | £7.5B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where GSK ranks in Health care
Dividends
It paid out £2.6B in cash dividends, 45% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | £2.6B | 45% |
| 2024 | n/a | £2.4B | 95% |
| 2023 | n/a | £2.2B | 46% |
| 2022 | n/a | £3.5B | 23% |
| 2021 | n/a | £4B | 91% |
| 2020 | n/a | £4B | 69% |
Latest SEC filings
What GSK plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026
- October 1, 2026
- September 24, 2026
- September 22, 2026
- September 15, 2026
- September 15, 2026
- September 14, 2026
- September 14, 2026
- September 11, 2026
- September 10, 2026
Insider trades
What the people running GSK plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns GSK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 5.8% | May 6, 2026 |
Largest institutional holders
Insiders
Questions about GSK
What does GSK plc do?
GSK is a biopharmaceutical company that researches, develops, and manufactures prescription medicines and vaccines. Its product portfolio focuses on infectious diseases, human immunodeficiency virus (HIV) treatments, immunology, and oncology. Its medicines and vaccines are sold to healthcare systems, hospitals, pharmacies, and governments globally. Its shares trade on NYSE under the ticker GSK.
What is GSK plc's net worth?
GSK plc has a market value (market cap) of $96.7B at the latest share price, and shareholders' equity of £16.4B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is GSK plc profitable?
Yes. In fiscal 2025 it reported net income of £5.7B on revenue of £32.7B, a net margin of 17.5%.
How much revenue does GSK plc make?
In fiscal 2025 GSK plc reported revenue of £32.7B. That is 4.1% more than a year earlier.
When did GSK plc last report?
Its newest filing of any kind is the foreign issuer update from October 6, 2026.
Similar companies
Compare GSK with
Follow GSK
Get an email when GSK plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values GSK plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.